Ilodecakin - ARMO Biosciences/Merck & Co
Alternative Names: AM 0010; LY-3500518; PEG-ilodecakin; PEG-rHuIL-10; Pegilodecakin - ARMO Biosciences/Merck & Co; PEGylated Human IL-10; PEGylated Interleukin-10; PEGylated recombinant human Interleukin-10Latest Information Update: 05 Nov 2023
At a glance
- Originator Merck & Co
- Developer ARMO Biosciences
- Class Anti-inflammatories; Antineoplastics; Immunotherapies; Interleukins; Polyethylene glycols
- Mechanism of Action Interleukin 10 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma
- Discontinued Fibrosis; Hypercholesterolaemia; Inflammatory bowel diseases
Most Recent Events
- 02 Jan 2023 No development reported - Phase-II for Non-small cell lung cancer (Combination therapy, Late-stage disease, Recurrent) in USA (SC) (NCT03382899)
- 02 Jan 2023 No development reported - Phase-II for Non-small cell lung cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (SC) (NCT03382912)
- 02 Jan 2023 No development reported - Phase-III for Pancreatic cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia, Austria, Belgium, Canada, Germany, France, Italy, South Korea, Spain, Taiwan, United Kingdom, Poland, USA (SC)